You are here: Welcome to the MPKB » Welcome to the MPKB » Non-MP therapies » Anti-TNF drugs
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Last revisionBoth sides next revision
home:othertreatments:antitnf [05.02.2011] – external edit 127.0.0.1home:othertreatments:antitnf [08.26.2017] – [Increased risk of infection] sallieq
Line 7: Line 7:
 Tumor necrosis factor-alpha or TNF-alpha is a cytokine critical for effective immune surveillance and is required for proper proliferation and function of natural killer cells, T cells, B cells, macrophages, and dendritic cells.(({{pubmed>long:16331857}})) Anti-TNF drugs, also known as TNF blockers, are drugs which interfere with the body's production of TNF-alpha.(({{pubmed>long: 18387510}})) Tumor necrosis factor-alpha or TNF-alpha is a cytokine critical for effective immune surveillance and is required for proper proliferation and function of natural killer cells, T cells, B cells, macrophages, and dendritic cells.(({{pubmed>long:16331857}})) Anti-TNF drugs, also known as TNF blockers, are drugs which interfere with the body's production of TNF-alpha.(({{pubmed>long: 18387510}}))
  
-Anti-TNF drugs are expensive, ineffective at treating chronic disease and have a number of adverse effects. +Anti-TNF drugs are expensive, ineffective at treating chronic disease and have a number of adverse effects. Also, anti-TNF inhibitors can make a patient feel temporarily less symptomatic, because they reduce immunopathology, the bacterial die-off reaction.
- +
-Anti-TNF drugs can make a patient feel temporarily less symptomatic, because they reduce immunopathology, the bacterial die-off reaction.+
  
  
Line 51: Line 49:
  
  
-[[http://www.fda.gov/medwatch/SAFETY/2001/remicadeTB_deardoc.pdf|According to Centocor]], the company which manufactures Remicade, patients taking the drug put themselves at increased risk for opportunistic infection.+[[https://google2.fda.gov/search?q=cache:8wrRnr956OEJ:www.accessdata.fda.gov/drugsatfda_docs/label/2002/inflcen062802lb.pdf+TNF-blocking+agents&client=FDAgov&output=xml_no_dtd&proxystylesheet=FDAgov&site=FDAgov&ie=UTF-8&access=p&oe=UTF-8|According to Centocor]], the company which manufactures Remicade, patients taking the drug put themselves at increased risk for opportunistic infection.
  
 <blockquote>Serious infections, including sepsis and pneumonia, have been reported in patients receiving TNF-blocking agents. Some of these infections have been fatal. <blockquote>Serious infections, including sepsis and pneumonia, have been reported in patients receiving TNF-blocking agents. Some of these infections have been fatal.
  
-//**U.S. Food and Drug Administration**//, [[http://www.fda.gov/MedWatch/safety/2006/Oct_PIs/Remicade_PI.pdf|2006 statement]]</blockquote>+//**U.S. Food and Drug Administration**//, [[https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/inflcen111099lb.pdf|page 6 : Warnings]]</blockquote>
  
 //M. tuberculosis// is one such infection.(({{pubmed>long:19565495}})) //M. tuberculosis// is one such infection.(({{pubmed>long:19565495}}))
Line 65: Line 63:
 To reduce the likelihood of contracting or exacerbating tuberculosis, prospective patients are routinely tested for infection via a skin test. However, as some researchers have noted, TB skin tests on patients treated with immunosupressants, which are routinely used on rheumatoid arthritis patients, are not reliable, because they result in false negatives.(({{pubmed>long:12614731}})) To reduce the likelihood of contracting or exacerbating tuberculosis, prospective patients are routinely tested for infection via a skin test. However, as some researchers have noted, TB skin tests on patients treated with immunosupressants, which are routinely used on rheumatoid arthritis patients, are not reliable, because they result in false negatives.(({{pubmed>long:12614731}}))
  
-"Exaggerated //Borreliosis// infections" have been noted(({{pubmed>long:20184613}})) as have been fatal fungal infections. In 2008, the FDA [[http://www.fda.gov/CDER/drug/InfoSheets/HCP/TNF_blockersHCP.htm|ordered stronger warnings]] on Enbrel, Remicade, Humira and Cimzia due to increased risk of fungal infections.+"Exaggerated //Borreliosis// infections" have been noted(({{pubmed>long:20184613}})) as have been fatal fungal infections. In 2008, the FDA ordered stronger warnings on Enbrel, Remicade, Humira and Cimzia due to increased risk of fungal infections.
  
 Researchers have also observed reactivation of latent viral infections, namely hepatitis B in patients who are chronic carriers of the virus. Researchers have also observed reactivation of latent viral infections, namely hepatitis B in patients who are chronic carriers of the virus.
Line 77: Line 75:
   * **Liver problems** – [[http://www.fda.gov/medwatch/SAFETY/2004/Remicade_12-22-04_PI.pdf|According to the FDA]], patients taking Remicade can (but rarely) experience severe hepatic reactions including acute liver failure, jaundice, hepatitis and cholestasis.   * **Liver problems** – [[http://www.fda.gov/medwatch/SAFETY/2004/Remicade_12-22-04_PI.pdf|According to the FDA]], patients taking Remicade can (but rarely) experience severe hepatic reactions including acute liver failure, jaundice, hepatitis and cholestasis.
   * **Skin problems** – In one prospective trial, 25% of patients on TNF-alpha-blocking therapy suffered from a dermatological condition that led them to visit a skin specialist. In a control group of patients who were not undergoing TNF-alpha blocking therapy and had less severe disease only 13% visited a dermatologist during the same period of time.(({{pubmed>long:15899052}}))   * **Skin problems** – In one prospective trial, 25% of patients on TNF-alpha-blocking therapy suffered from a dermatological condition that led them to visit a skin specialist. In a control group of patients who were not undergoing TNF-alpha blocking therapy and had less severe disease only 13% visited a dermatologist during the same period of time.(({{pubmed>long:15899052}}))
-  * **Cancer** – One recent systematic review of the adverse effects of anti-TNF therapies as they were used in rheumatoid arthritis concluded that patients taking the drugs are at 3.3 times higher risk for "malignancies."(({{pubmed>long:16705109}})) The study's authors concluded that these side effects were dose-dependent. Since then, the FDA has issued [[http://www.fda.gov/CDER/drug/early_comm/TNF_blockers.htm|an early communication]]  about an ongoing investigation of approximately 30 reports of cancer in children and young adults.+  * **Cancer** – One recent systematic review of the adverse effects of anti-TNF therapies as they were used in rheumatoid arthritis concluded that patients taking the drugs are at 3.3 times higher risk for "malignancies."(({{pubmed>long:16705109}})) The study's authors concluded that these side effects were dose-dependent. Since then, the FDA has issued [[http://www.fda.gov/CDER/drug/early_comm/TNF_blockers.htm|an early communication]]  about an ongoing investigation of approximately 30 reports of cancer in children and young adults. More recently, a study of over 20,000 US military veterans show that nonmelanoma skin cancer risk is about one third higher for patients with rheumatoid arthritis treated with TNF inhibitors than for similar patients treated with nonbiologic disease-modifying antirheumatic drugs (DMARDs).(({{pubmed>long:21415022}}))
  
  
Line 99: Line 97:
  
 ===== Notes and comments ===== ===== Notes and comments =====
-EDIT+
  
   * Legacy content   * Legacy content
     * http://www.marshallprotocol.com/view_topic.php?id=3094&forum_id=37&jump_to=28080#p28080 s32     * http://www.marshallprotocol.com/view_topic.php?id=3094&forum_id=37&jump_to=28080#p28080 s32
 ===== References ===== ===== References =====
home/othertreatments/antitnf.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.